133 related articles for article (PubMed ID: 38026448)
1. The Clinical Relevance and Functional Implications of Thymosin Beta-10 in Glioma.
Li W; Chen J; Xiang C; Long Y; Wu K; Li J
Genet Res (Camb); 2023; 2023():5517445. PubMed ID: 38026448
[TBL] [Abstract][Full Text] [Related]
2. Pan-cancer analysis identifies the correlations of Thymosin Beta 10 with predicting prognosis and immunotherapy response.
Li Z; Li Y; Tian Y; Li N; Shen L; Zhao Y
Front Immunol; 2023; 14():1170539. PubMed ID: 37275863
[TBL] [Abstract][Full Text] [Related]
3. TMSB10 acts as a biomarker and promotes progression of clear cell renal cell carcinoma.
Pan Q; Cheng G; Liu Y; Xu T; Zhang H; Li B
Int J Oncol; 2020 May; 56(5):1101-1114. PubMed ID: 32319572
[TBL] [Abstract][Full Text] [Related]
4. Pancancer landscape analysis of the thymosin family identified TMSB10 as a potential prognostic biomarker and immunotherapy target in glioma.
Xiong Y; Qi Y; Pan Z; Wang S; Li B; Feng B; Xue H; Zhao R; Li G
Cancer Cell Int; 2022 Sep; 22(1):294. PubMed ID: 36163046
[TBL] [Abstract][Full Text] [Related]
5. Thymosin β10 promotes tumor-associated macrophages M2 conversion and proliferation via the PI3K/Akt pathway in lung adenocarcinoma.
Zeng J; Yang X; Yang L; Li W; Zheng Y
Respir Res; 2020 Dec; 21(1):328. PubMed ID: 33349268
[TBL] [Abstract][Full Text] [Related]
6. Thymosin β 10 is overexpressed and associated with unfavorable prognosis in hepatocellular carcinoma.
Song C; Su Z; Guo J
Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30787051
[TBL] [Abstract][Full Text] [Related]
7. Thymosin beta 10 is a key regulator of tumorigenesis and metastasis and a novel serum marker in breast cancer.
Zhang X; Ren D; Guo L; Wang L; Wu S; Lin C; Ye L; Zhu J; Li J; Song L; Lin H; He Z
Breast Cancer Res; 2017 Feb; 19(1):15. PubMed ID: 28179017
[TBL] [Abstract][Full Text] [Related]
8. DNMT1 maintains the methylation of miR-152-3p to regulate TMSB10 expression, thereby affecting the biological characteristics of colorectal cancer cells.
Wang C; Ma X; Zhang J; Jia X; Huang M
IUBMB Life; 2020 Nov; 72(11):2432-2443. PubMed ID: 32918845
[TBL] [Abstract][Full Text] [Related]
9. TMSB10, a potential prognosis prediction biomarker, promotes the invasion and angiogenesis of gastric cancer.
Yan Z; Yan Q; Song Y; Wang L
J Gastroenterol Hepatol; 2021 Nov; 36(11):3102-3112. PubMed ID: 34114679
[TBL] [Abstract][Full Text] [Related]
10. PTEN/AKT upregulation of TMSB10 contributes to lung cancer cell growth and predicts poor survival of the patients.
Li J; Zhou S; Li H; Xu Y; Zhou N; Liu R
Biosci Biotechnol Biochem; 2021 Mar; 85(4):805-813. PubMed ID: 33686397
[TBL] [Abstract][Full Text] [Related]
11. PLEKHA4 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Glioma.
Zhang W; Li L; Bian PP; Luo QP; Xiong ZT
Biomed Res Int; 2023; 2023():4504474. PubMed ID: 36714030
[TBL] [Abstract][Full Text] [Related]
12. TMSB10 Promotes Progression of Clear Cell Renal Cell Carcinoma via JUN Transcription Regulation.
Wang C; He Y; You Z; Chen X
Ann Clin Lab Sci; 2022 Mar; 52(2):230-239. PubMed ID: 35414502
[TBL] [Abstract][Full Text] [Related]
13. Thymosin beta 10 correlates with lymph node metastases of papillary thyroid carcinoma.
Zhang XJ; Su YR; Liu D; Xu DB; Zeng MS; Chen WK
J Surg Res; 2014 Dec; 192(2):487-93. PubMed ID: 24974154
[TBL] [Abstract][Full Text] [Related]
14. Hypomethylation of the thymosin β(10) gene is not associated with its overexpression in non-small cell lung cancer.
Lee SM; Na YK; Hong HS; Jang EJ; Yoon GS; Park JY; Kim DS
Mol Cells; 2011 Oct; 32(4):343-8. PubMed ID: 22038593
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of thymosin β10 correlates with disease progression and poor prognosis in bladder cancer.
Wang B; Wang Z; Zhang T; Yang G
Exp Ther Med; 2019 Nov; 18(5):3759-3766. PubMed ID: 31616507
[TBL] [Abstract][Full Text] [Related]
16. Adenylate kinase 2 is a biomarker related to the prognosis of glioma and the immune microenvironment.
Liu Z; Tang C; Teng X; Mohamed ZA; Fan J
J Clin Lab Anal; 2023 Apr; 37(8):e24892. PubMed ID: 37161605
[TBL] [Abstract][Full Text] [Related]
17. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
18. Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas.
Sabha N; Knobbe CB; Maganti M; Al Omar S; Bernstein M; Cairns R; Çako B; von Deimling A; Capper D; Mak TW; Kiehl TR; Carvalho P; Garrett E; Perry A; Zadeh G; Guha A; Sidney Croul
Neuro Oncol; 2014 Jul; 16(7):914-23. PubMed ID: 24470545
[TBL] [Abstract][Full Text] [Related]
19. CCDC103 as a Prognostic Biomarker Correlated with Tumor Progression and Immune Infiltration in Glioma.
Xu Z; Xu H; Chen X; Huang X; Tian J; Zhao J; Liu B; Shi F; Wu J; Pu J
Onco Targets Ther; 2023; 16():819-837. PubMed ID: 37873495
[TBL] [Abstract][Full Text] [Related]
20. Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology.
Mehani B; Asanigari S; Chung HJ; Dazelle K; Singh A; Hannenhalli S; Aldape K
Acta Neuropathol Commun; 2022 Feb; 10(1):19. PubMed ID: 35144680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
